EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC-ND 4.0

Pharmacokinetic-Pharmacodynamic Determinants of Clinical Outcomes for Rifampin-Resistant Tuberculosis: A Multisite Prospective Cohort Study

Scott K Heysell, Stellah G Mpagama, Oleg B Ogarkov, Mark Conaway, Shahriar Ahmed, Svetlana Zhdanova, Suporn Pholwat, Mohammad H Alshaer, Anna M Chongolo, Buliga Mujaga, Margaretha Sariko, Sabrina Saba und 13 weitere

Clinical Infectious Diseases · 2023

DOI: 10.1093/cid/ciac511 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Clinical Infectious Diseases, 2023. Verfasst von Scott K Heysell und 24 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, Virginia, USA. Hauptthemen laut MEDLINE: Tuberculosis, Multidrug-Resistant, Tuberculosis, Pulmonary, Mycobacterium tuberculosis. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases of the National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Rifampin-resistant and/or multidrug-resistant tuberculosis (RR/MDR-TB) treatment requires multiple drugs, and outcomes remain suboptimal. Some drugs are associated with improved outcome. It is unknown whether particular pharmacokinetic-pharmacodynamic relationships predict outcome.

Methods

Adults with pulmonary RR/MDR-TB in Tanzania, Bangladesh, and the Russian Federation receiving local regimens were enrolled from June 2016 to July 2018. Serum was collected after 2, 4, and 8 weeks for each drug’s area under the concentration-time curve over 24 hours (AUC0–24). Quantitative susceptibility of the M. tuberculosis isolate was measured by minimum inhibitory concentrations (MICs). Individual drug AUC0–24/MIC targets were assessed by adjusted odds ratios (ORs) for favorable treatment outcome, and hazard ratios (HRs) for time to sputum culture conversion. K-means clustering algorithm separated the cohort of the most common multidrug regimen into 4 clusters by AUC0–24/MIC exposures.

Results

Among 290 patients, 62 (21%) experienced treatment failure, including 30 deaths. Moxifloxacin AUC0–24/MIC target of 58 was associated with favorable treatment outcome (OR, 3.75; 95% confidence interval, 1.21–11.56; P = .022); levofloxacin AUC0–24/MIC of 118.3, clofazimine AUC0–24/MIC of 50.5, and pyrazinamide AUC0–24 of 379 mg × h/L were associated with faster culture conversion (HR >1.0, P < .05). Other individual drug exposures were not predictive. Clustering by AUC0–24/MIC revealed that those with the lowest multidrug exposures had the slowest culture conversion.

Conclusions

Amidst multidrug regimens for RR/MDR-TB, serum pharmacokinetics and M. tuberculosis MICs were variable, yet defined parameters to certain drugs—fluoroquinolones, pyrazinamide, clofazimine—were predictive and should be optimized to improve clinical outcome. Clinical Trials Registration NCT03559582.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tuberculosis, Multidrug-ResistantTuberculosis, PulmonaryMycobacterium tuberculosisAdultHumansAntitubercular AgentsRifampinPyrazinamideProspective StudiesClofazimineMicrobial Sensitivity Tests

Stichwörter der Autor:innen

minimum inhibitory concentrationsmultidrug-resistant tuberculosispharmacodynamicspharmacokinetics

Substanzen

Antitubercular AgentsRifampinPyrazinamideClofazimine

Autor:innen und Institutionen

  • Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, Virginia, USA.
  • Kibong'oto Infectious Diseases Hospital, Sanya Juu, Tanzania.
  • Kilimanjaro Clinical Research Institute and Kilimanjaro Christian Medical University College, Moshi, Tanzania.
  • Department of Epidemiology and Microbiology, Scientific Centre for Family Health and Human Reproduction Problems, Irkutsk, Russian Federation.
  • Department of Public Health Sciences, University of Virginia, Charlottesville, Virginia, USA.
  • International Center for Diarrheal Diseases Research, Bangladesh, Dhaka, Bangladesh.

Förderung

  • NIAID NIH HHS
  • National Institute of Allergy and Infectious Diseases of the National Institutes of Health

Zitieren

APA

Heysell, S. K., Mpagama, S. G., Ogarkov, O. B., Conaway, M., Ahmed, S., Zhdanova, S., Pholwat, S., Alshaer, M. H., Chongolo, A. M., Mujaga, B., Sariko, M., Saba, S., Rahman, S. M. M., Uddin, M. K. M., Suzdalnitsky, A., Moiseeva, E., Zorkaltseva, E., Koshcheyev, M., Vitko, S., …, & Houpt, E. R. (2023). Pharmacokinetic-Pharmacodynamic Determinants of Clinical Outcomes for Rifampin-Resistant Tuberculosis: A Multisite Prospective Cohort Study. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciac511

Vancouver

Heysell SK, Mpagama SG, Ogarkov OB, Conaway M, Ahmed S, Zhdanova S, et al. Pharmacokinetic-Pharmacodynamic Determinants of Clinical Outcomes for Rifampin-Resistant Tuberculosis: A Multisite Prospective Cohort Study. Clinical Infectious Diseases. 2023. doi:10.1093/cid/ciac511

BibTeX
@article{Heysell2023,
  author = {Heysell, Scott K and Mpagama, Stellah G and Ogarkov, Oleg B and Conaway, Mark and Ahmed, Shahriar and Zhdanova, Svetlana and Pholwat, Suporn and Alshaer, Mohammad H and Chongolo, Anna M and Mujaga, Buliga and Sariko, Margaretha and Saba, Sabrina and Rahman, S M Mazidur and Uddin, Mohammad Khaja Mafij and Suzdalnitsky, Alexey and Moiseeva, Elena and Zorkaltseva, Elena and Koshcheyev, Mikhail and Vitko, Serhiy and Mmbaga, Blandina T and Kibiki, Gibson S and Pasipanodya, Jotam G and Peloquin, Charles A and Banu, Sayera and Houpt, Eric R},
  title = {Pharmacokinetic-Pharmacodynamic Determinants of Clinical Outcomes for Rifampin-Resistant Tuberculosis: A Multisite Prospective Cohort Study},
  journal = {Clinical Infectious Diseases},
  year = {2023},
  doi = {10.1093/cid/ciac511}
}
Kostenlos starten →